
COVID-19 Adult Quick Clinical Guide: Initial Considerations and Workup

Clinical Manifestations

- Fever 44-94% (less common earlier in course)
- Cough 68-83%
- Anosmia and/or aegeusia ~70%
- Myalgias 11-15%
- Shortness of breath 11-40%
- URI symptoms 5-25%
- GI symptoms 3-17%


High Risk Groups

- Demographics: older age, male
- Comorbidities: cardiovascular disease, HTN, obesity, pulmonary disease, diabetes, malignancy, immunosuppression



+If no alternative diagnosis and high suspicion for COVID-19 despite negative test, continue isolation and repeat NP swab in 2-4 days

Saloni Kumar, MD, Julia Caton, MD, Neera Ahuja, MD, Meghan Ramsey, MD, Stanford University Department of Medicine; Updated 6/23/20



Duration of Symptoms (<u>Zhou et al</u>, <u>Lancet</u>, 2020; Young et







Testing Guidelines

All hospitalized patients should receive **COVID-19** testing

Santa Clara County Health Department testing guidelines found here (5/2/20)

 California Health Department guidelines found here (5/1/20)

SHC interventional platform testing criteria and protocols for procedures and surgeries found here (6/1/20)

Lab and Imaging Results in **COVID-19**

Labs

CBC with lymphopenia* (35-83%) and variable white blood cell count Elevated AST/ALT* (28-38%) Elevated CRP* Elevated d-dimer* Elevated troponin*

Normal procalcitonin (though can be elevated in those requiring ICU care) *Potential marker of disease severity

Studies

• CXR – variable, bilateral patchy

- opacities most common
- CT ground glass opacification with
 - or without consolidative
 - abnormalities; more likely bilateral
 - with peripheral distribution

COVID-19 Adult Quick Clinical Guide: Inpatient Management


Respiratory Management

- SHC COVID-19 Oxygen Support Guidelines (5/26/20)
- PUI or COVID-19-positive patients receiving oxygen via nasal prongs should have a surgical mask that covers their nose and mouth when any provider is in the room
- Switch to a non-rebreather (NRB) mask if > 6 LPM of oxygen is required
- High Flow Nasal Cannula may be considered in the ICU setting if the patient is on 15LPM via NRB and PO2 < 65 or SaO2 < 92%.
- NIPPV (CPAP or BIPAP) may be used in select patients only.
- requiring supplemental oxygen following these <u>SHC Guidelines</u>

Monitoring Labs/Studies

- Daily or QOD (based on clinical judgment): CBC with differential and CMP
- Trend DIC panel every 3 days if stable (increase to daily if abnormal)

Discharge Considerations



Discharge with instructions for self quarantine – refer to patient's home county health department guidelines


Obtain health department approval prior to discharge for residents of San Mateo and San Francisco counties (not required for Santa Clara County)

Discharge medications picked up by family members or delivered to bedside

Currently no guidance to obtain repeat COVID testing

Saloni Kumar, MD, Julia Caton, MD, Neera Ahuja, MD, Meghan Ramsey, MD, Stanford University Department of Medicine; Updated 6/23/20

Consider trial of awake proning in patients with respiratory symptoms or



When to Call the ICU

Provider Concern

Respiratory Distress (needing > 4L NC to maintain Spo2 >92% or PaO2 > 65, rapid escalation of O2 requirement, or significant work of breathing) Hemodynamic instability after initial conservative fluid resuscitation Severe comorbid illness or high concern for deterioration

COVID-19 and PUI Decedent Care (SHC Guidelines 4/12/20) For all COVID/PUI deaths:

Provider immediately contacts coroner: 408-793-1900, ext. 2 If coroner releases the case, approach family for Consent for Autopsy at Stanford Infection Prevention and Control to notify Public Health Department of patient's county of residence

For cause of death, list <cause A,B,C> due to COVID-19; if PUI do not mention COVID-19 (Decedent Care Chaplain will amend if positive) Questions? Contact decedent care chaplain via Voalte or pager 25683



*AMA Discharges (SHC Guidelines 3/22/20) Patients who have capacity and who want to refuse medical treatment or hospitalization have the legal

•For concerns about capacity, page Ethics (#16230) or Voalte the on-call Ethics consultant

•Discuss with the patient the risks of leaving and document discussion in the chart including the reason the patient wants to leave.

•Notify the patient that we are required to contact the Public Health Department and document this

•Request that the patient sign the AMA form and scan form into EPIC. If the patient refuses to sign, document their refusal in the chart.

•Contact Santa Clara County Public Health Department. Phone: (408) 885-4214 Email: disease@phd.sccgov.org

COVID-19 Adult Quick Clinical Guide: Therapeutics

For a literature review of experimental therapies, click here.

IV fluids

Antibiotics

•Only use if concern for superinfection – use procalcitonin for guidance

Anti-pyretics

•ACE2 receptor which SARS-CoV-2 binds to is upregulated by NSAIDS

Bronchodilators

Increased risk of aerosolization with nebulizers compared to MDI

Anticoagulation (adapted from Stanford Hematology)

- Initiate SCDs <u>and</u> prophylactic anticoagulation unless contraindication
- Treatment dose anticoagulation NOT recommended by Stanford Hematology at this time in the absence of confirmed or strongly suspected thrombosis
- DOACs are not first choice due to drug-drug interactions with antivirals and interference with anti-Xa monitoring
- Post-discharge VTE prophylaxis
 - into consieration.
 - Reasonable post-discharge VTE prophaylxis regimens:

 - Enoxaparin 40 mg daily x 2-4 weeks

Mucolytics

 Infection can lead to thick secretions/mucous plugs but airway clearance treatment can increase aerosolization

Saloni Kumar, MD, Julia Caton, MD, Neera Ahuja, MD, Meghan Ramsey, MD, Stanford University Department of Medicine; Updated 6/23/20

COVID-19 Supportive Treatment

• Consider in patients with additional VTE risk factors such as older age, obesity, active cancer, or immobilization. Bleeding risk must be taken

Rivaroxaban 10 mg daily for 31-39 days (MAGELLAN trial)



Use *conservative* fluid management to mitigate risk of progression of respiratory failure

Refer to CAP guidelines

- •WHO does NOT recommend against using NSAIDs •Can use acetaminophen as needed (check LFTs)
- •Use MDI over nebulizers

VTE prophylaxis for non-ICU patients:

Weight	CrCl > 30	CrCl < 30
< 50 kg	Enoxaparin 30 mg daily	Unfractionated heparin 5000 units BID
50-100 kg	Enoxaparin 40 mg daily	Enoxaparin 30 mg daily if CrCl 15-30 (preferred) or unfractionated heparin 5000 units TID
> 100 kg or BMI > 40	Enoxaparin 40 mg BID or 0.5 mg/kg daily	Unfractionated heparin 7500 units TID

VTE prophylaxis for ICU patients:

Weight	CrCl > 30	CrCl < 30
< 60 kg	Enoxaparin 30 mg BID	Unfractionated heparin 5000 units BID-TID
60-100 kg	Enoxaparin 40 mg BID	Unfractionated heparin 10000 units BID
> 100 kg or BMI > 40	Enoxaparin 0.5 mg/kg BID	Unfractionated heparin 10000 units TID

Therapeutic anticoagulation:

Goal platelet count > 50 K, if less, consult Hematology. Discuss dosing with pharmacy if CrCl 30-60. Use UFH if CrCl < 30.

Weight	Enoxaparin (CrCl > 60)	
40-150 kg	1 mg/kg every 12 hours	
> 150 kg	0.75 mg/kg every 12 hours	

•Do NOT use flutter valve and cough assist devices without Pulmonary consult

If contraindication to enoxaparin, use UFH

Follow heparin protocol based and and adjust for goal anti-Xa 0.3-0.7 units/mL

COVID-19 Adult Quick Clinical Guide: Chronic Medications and Organ System Involvement

ACEi/ARB •ACE2 receptor which SARS-CoV-2 binds to is upregulated by ACEi/ARB

Statins

Pulmonary

- •Dry cough (59%)
- •Dyspnea (31%) \rightarrow if not a presenting symptoms, develops at 5-8 days after admission
- •Sputum production (27%)
- •Pneumonia with bilateral patchy infiltrates
- •ARDS (20%) \rightarrow about 8-12 days after diagnosis
- •Acute hypoxic respiratory failure \rightarrow rapid progression to intubation (12-24 hours)

Renal

- •AKI in 2-29% of patients
- •Etiology primarily ATN due to direct cellular injury from virus or shock •Proteinuria (44%)
- •Hematuria (26.9%)
- •Renal replacement therapy needed in 1-5% of hospitalized patients and associated with worse outcomes

GI

- •Gl symptoms (nausea/diarrhea) manifested before respiratory symptoms about 10% of the time
- •Diarrhea (2-10%) \rightarrow COVID+ stool test •Elevated ALT or AST (53%)

Saloni Kumar, MD, Julia Caton, MD, Neera Ahuja, MD, Meghan Ramsey, MD, Stanford University Department of Medicine; Updated 6/23/20

COVID-19 Chronic Medication Management

COVID 19 Organ System Involvement

•Per the ACC/AHA/HFSA \rightarrow do NOT discontinue ACEi/ARB in patients who are already taking them

- •Per the ACC, continue statin if already on one (unless acute rhabdomyolysis)
- •Unclear data on initiating a statin as novel therapy, but currently no harm shown

Cardiac

- •Acute cardiac injury in 7-22% of hospitalized patients •ACS
- •Stress cardiomyopathy/heart failure
- •Demand ischemia
- •Viral myocarditis
- Arrhythmia (17%)
- Shock was rarely a presenting sign and usually presented after days of critical illness

Hematologic

- •Cytokine storm and secondary HLH
- Increased risk of VTE
- •DIC (median 4 days from hospitalization)
- •Microthrombi in pulmonary vasculature
- •Lymphopenia, \clubsuit LDH, \bigstar ferritin, \bigstar D-Dimer

ENT

• Loss of smell or taste

COVID-19 Adult Quick Clinical Guide: References

- doi:10.1148/radiol.2020200230
- 17.
- 2020;200432. doi:10.1148/radiol.2020200432

- bytheir-physician (Accessed on March 23, 2020)

- and-dysgeusia-symptoms-coronavirus-disease

1. Brigham and Women's Hospital COVID-19 Critical Care Clinical Guidelines. Updated March 23, 2020. covidprotocols.org 2. Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020;295(1):202–207.

3. Gao Y, Li T, Han M, et al. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. J Med Virol. 2020 Mar

4. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. 5. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR [published online ahead of print, 2020 Feb 19]. Radiology.

6. Massachusetts General Hospital COVID-19 Treatment Guidance. Updated March 17, 2020. 7. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020 Mar 16 8. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 3. DOI: 10.1007/s00134-020-05991-x. PMID: 32125452.

9. Santa Clara County Public Health. "What to do if you have confirmed COVID. <u>https://www.sccgov.org/sites/phd-p/Diseases/novel-</u> coronavirus/Documents/Confirmed-Case-Information-Sheet-20200316.pdf. 10. Shah, N. Higher Co-infction rates in COVID-19. https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333. March 18, 2020. 11. Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology. Patients taking ACE-I and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-

12. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J *Thromb Haemost*. 2020 Feb. DOI: 10.1111/jth.14768. PMID: 32073213. 13. WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID-19 Symptoms. Science Alert 2020. https://www.sciencealert.com/whorecommendsto-avoid-taking-ibuprofen-for-covid-19-symptoms (Accessed on March 23, 2020). 14. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 15. Xianghong Y, Renhua S, Dechang C. [Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored]. Natl Med J China. 2020;100(00):E017-E017. DOI: 10.3760/cma.j.cn112137-20200229-00520. PMID: 32145717. 16. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 11;S0140-6736(20)30566-3. DOI: 10.1016/S0140-6736(20)30566-3. PMID: 32171076. 17. AAO-HNS: Anosmia, Hyposmia, and Dysgeusia Symptoms of Coronavirus Disease. <u>https://www.entnet.org/content/aao-hns-anosmia-hyposmia-</u>